Underutilization of clopidogrel and glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute coronary syndrome patients: The Canadian Global Registry of Acute Coronary Events (GRACE) experience

American Heart Journal

Volumn 158, Issue 6, 2009, Pages 917-924

  Banihashemi, Behnam ^a   Goodman, Shaun G ^a   Yan, Raymond T ^a   Welsh, Robert C ^b   Mehta, Shamir R ^c   Montalescot, Gilles ^d   Kornder, Jan M ^e   Wong, Graham C ^f   Gyenes, Gabor ^b   Steg, Ph Gabriel ^g   Yan, Andrew T ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e SURREY MEMORIAL HOSPITAL   (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLEEDING; CANADA; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DISEASE REGISTRY; DRUG UTILIZATION; FEMALE; HEART CATHETERIZATION; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HIGH RISK POPULATION; HOSPITAL ADMISSION; HUMAN; INVASIVE PROCEDURE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INVASIVE PROCEDURE; PATIENT ASSESSMENT; PATIENT CODING; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; ST SEGMENT ELEVATION;

ACUTE CORONARY SYNDROME; AGED; CANADA; DRUG UTILIZATION; FEMALE; GUIDELINE ADHERENCE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROSPECTIVE STUDIES; REGISTRIES; RETROSPECTIVE STUDIES; TICLOPIDINE;

EID: 70849112420     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2009.09.016     Document Type: Article

References (36)

1. Yusuf S., Zhao F., Mehta S.R., et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
2. Budaj A., Yusuf S., Mehta S.R., et al. Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation 106 (2002) 1622-1626
3. Kastrati A., Mehilli J., Neumann F.J., et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 295 (2006) 1531-1538
4. Anderson J.L., Adams C.D., Antman E.M., et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 50 (2007) e1-e157
5. Peterson E.D., Pollack Jr. C.V., Roe M.T., et al. Early use of glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute myocardial infarction: observations from the National Registry of Myocardial Infarction 4. J Am Coll Cardiol 42 (2003) 45-53
6. Tricoci P., Peterson E.D., Roe M.T., et al. Patterns of guideline adherence and care delivery for patients with unstable angina and non-ST-segment elevation myocardial infarction (from the CRUSADE Quality Improvement Initiative). Am J Cardiol 98 (2006) 30Q-35Q
7. Alexander D., Ou F.S., Roe M.T., et al. Use of and in-hospital outcomes after early clopidogrel therapy in patients not undergoing an early invasive strategy for treatment of non-ST-segment elevation myocardial infarction: (from the CRUSADE Quality Improvement Initiative). Am Heart J 156 (2008) 606-612
8. Bromberg-Marin G., Marin-Neto J.A., Parsons L.S., et al. Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction(from the National Registry of Myocardial Infarction-4). Am J Cardiol 98 (2006) 1125-1131
9. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms(PRISM-PLUS)Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 338 (1998) 1488-1497
10. Simoons M.L., and GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomized trial. Lancet 357 (2001) 1915-1924
11. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. N Engl J Med 339 (1998) 436-443
12. GRACE Investigators. Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project: a multinational registry of patients hospitalized with acute coronary syndromes. Am Heart J 141 (2001) 190-199
13. University of Massachusetts Medical School-Centre for Outcomes Research. GRACE overview. Available at:. http://www.outcomes.org/grace Last accessed Sep 10, 2009
14. Granger C.B., Goldberg R.J., Dabbous O., et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 163 (2003) 2345-2353
15. Yan A.T., Jong P., Yan R.T., et al. Clinical trial-derived risk model may not generalize to real-world patients with acute coronary syndrome. Am Heart J 148 (2004) 1020-1027
16. Yan A.T., Yan R.T., Tan M., et al. Risk scores for risk stratification in acute coronary syndromes: useful but simpler is not necessarily better. Eur Heart J 28 (2007) 1072-1078
17. Mehta S.R., Yusuf S., Peters R.J., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 (2001) 527-533
18. Roe M.T., Peterson E.D., Newby L.K., et al. The influence of risk status on guideline adherence for patients with non-ST-segment elevation acute coronary syndromes. Am Heart J 151 (2006) 1205-1213
19. Yan A.T., Yan R.T., Tan M., et al. Management patterns in relation to risk stratification among patients with non-ST elevation acute coronary syndromes. Arch Intern Med 167 (2007) 1009-1016
20. Yusuf S., Mehta S.R., Zhao F., et al. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 107 (2003) 966-972
21. Mehta R.H., Chen A.Y., Pollack Jr. C.V., et al. Challenges in predicting the need for coronary artery bypass grafting at presentation in patients with non-ST-segment elevation acute coronary syndromes. Am J Cardiol 98 (2006) 624-627
22. Chew D.P., Mahaffey K.W., White H.D., et al. Coronary artery bypass surgery in patients with acute coronary syndromes is difficult to predict. Am Heart J 155 (2008) 841-847
23. Mehta R.H., Roe M.T., Mulgund J., et al. Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery. J Am Coll Cardiol 48 (2006) 281-286
24. Fox K.A., Mehta S.R., Peters R., et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 110 (2004) 1202-1208
25. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina. Lancet 349 (1997) 1429-1435
26. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 330 (1994) 956-961
27. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 336 (1997) 1689-1696
28. EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 352 (1998) 87-92
29. Boersma E., Harrington R.A., Moliterno D.J., et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 359 (2002) 189-198
30. Kastrati A., Mehilli J., Schuhlen H., et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 350 (2004) 232-238
31. Pieper K.S., Tsiatis A.A., Davidian M., et al. Differential treatment benefit of platelet glycoprotein IIb/IIIa inhibition with percutaneous coronary intervention versus medical therapy for acute coronary syndromes: exploration of methods. Circulation 109 (2004) 641-646
32. Rao R.V., Goodman S.G., Yan R.T., et al. Temporal trends and patterns of early clopidogrel use across the spectrum of acute coronary syndromes. Am Heart J 157 (2009) 642-650
33. Giugliano R.P., White J.A., Bode C., et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med 360 (2009) 2176-2190
34. Stone G.W., Bertrand M.E., Moses J.W., et al. Routine upstream initiation versus deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing Trial. JAMA 297 (2007) 591-602
35. Subherwal S., Bach R.G., Chen A.Y., et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. Circulation 119 (2009) 1873-1882
36. Peters R.J., Mehta S.R., Fox K.A., et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 108 (2003) 1682-1687